Evaluation of ASHB-5 and ASHB-6 Complexes as Novel Anti-Inflammatory Candidates Using Carrageenan-Induced Paw Edema and Molecular Docking Approaches
Trends in Sciences · 01.10.2026 · 24 (2) · 14543
DOI: 10.48048/tis.2027.14543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Sciences, online erschienen am 01.10.2026. Verfasst von Dadamirzayeva Kamola und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Inflammation is a complex biological response regulated by multiple mediators, enzymes, cytokines, and intracellular signaling pathways. The present study aimed to evaluate the anti-inflammatory potential of ASHB-5 and ASHB-6 complexes using an integrated in vivo and in silico approach. The anti-exudative activity of the complexes was investigated in rats using the carrageenan-induced paw edema model. ASHB-5 and ASHB-6 were administered orally at doses of 12.5 and 25 mg/kg, and paw edema development was monitored after carrageenan injection. Molecular docking analysis was performed against key inflammation-related targets, including cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), mitogen-activated protein kinase (MAPK), and nuclear factor-kappa B (NF-kB), to explore possible molecular mechanisms underlying the observed effects. In vivo results showed that both ASHB-5 and ASHB-6 reduced carrageenan-induced paw edema in a dose-dependent manner. At 12.5 mg/kg, ASHB-5 demonstrated stronger anti-exudative activity than ASHB-6, with inhibition values of 42.9 ± 5.1% and 28.4 ± 3.7%, respectively. At 25 mg/kg, ASHB-6 produced the most pronounced effect, reaching 64.6 ± 4.8% inhibition, whereas ASHB-5 showed 52.1 ± 4.6% activity. These findings indicate that ASHB-5 was more effective at the lower dose, while ASHB-6 exhibited greater activity at the higher dose. Docking analysis revealed favorable predicted interactions of both complexes with COX-2, IL-6, MAPK, and NF-kB. Particularly strong binding profiles were observed for COX-2 and NF-kB, especially for ASHB-6, which showed the strongest predicted interaction with NF-kB. Overall, the combined in vivo and in silico findings suggest that ASHB-5 and ASHB-6 may exert anti-inflammatory effects through multi-target mechanisms involving prostaglandin-mediated inflammation, cytokine-related signaling, MAPK-associated intracellular pathways, and NF-kB-mediated transcriptional regulation. These results support further pharmacological investigation of ASHB-5 and ASHB-6 as potential multi-target anti-inflammatory candidates. HIGHLIGHTS ASHB-5 and ASHB-6 reduced carrageenan-induced paw edema in rats. Both complexes showed dose-dependent anti-exudative activity. ASHB-5 was more active at 12.5 mg/kg, while ASHB-6 was strongest at 25 mg/kg. ASHB-6 produced the highest inhibition of edema formation, reaching 64.6 ± 4.8%. Molecular docking showed favorable interactions with COX-2, IL-6, MAPK, and NF-κB. ASHB-6 demonstrated particularly strong predicted binding with COX-2 and NF-κB. Integrated in vivo and in silico findings suggest multi-target anti-inflammatory mechanisms. GRAPHICAL ABSTRACT
Zitieren
APA
Kamola, D., Muazzam, B., Akmaljon, N., Zhedgerovich, R. K., Alimbayeva, S. B. K., & Khodzhaniyazov, B. A. (2026). Evaluation of ASHB-5 and ASHB-6 Complexes as Novel Anti-Inflammatory Candidates Using Carrageenan-Induced Paw Edema and Molecular Docking Approaches. Trends in Sciences, 24(2), 14543. https://doi.org/10.48048/tis.2027.14543
Vancouver
Kamola D, Muazzam B, Akmaljon N, Zhedgerovich RK, Alimbayeva SBK, Khodzhaniyazov BA. Evaluation of ASHB-5 and ASHB-6 Complexes as Novel Anti-Inflammatory Candidates Using Carrageenan-Induced Paw Edema and Molecular Docking Approaches. Trends in Sciences. 2026;24(2):14543. doi:10.48048/tis.2027.14543
BibTeX
@article{Kamola2026,
author = {Kamola, Dadamirzayeva and Muazzam, Bakiyeva and Akmaljon, Najimov and Zhedgerovich, Rezhepov Kural and Alimbayeva, Shiyrin Bekniyaz Kizi and Khodzhaniyazov, Bekniyaz Alimbayevich},
title = {Evaluation of ASHB-5 and ASHB-6 Complexes as Novel Anti-Inflammatory Candidates Using Carrageenan-Induced Paw Edema and Molecular Docking Approaches},
journal = {Trends in Sciences},
year = {2026},
volume = {24},
number = {2},
pages = {14543},
doi = {10.48048/tis.2027.14543}
}
EUVIMED